[go: up one dir, main page]

TR200000482T2 - N-Aroilfenilalanin türevleri. - Google Patents

N-Aroilfenilalanin türevleri.

Info

Publication number
TR200000482T2
TR200000482T2 TR2000/00482T TR200000482T TR200000482T2 TR 200000482 T2 TR200000482 T2 TR 200000482T2 TR 2000/00482 T TR2000/00482 T TR 2000/00482T TR 200000482 T TR200000482 T TR 200000482T TR 200000482 T2 TR200000482 T2 TR 200000482T2
Authority
TR
Turkey
Prior art keywords
compounds
cells
vcam
vla
aroylphenylalanine
Prior art date
Application number
TR2000/00482T
Other languages
English (en)
Inventor
Chen Li
William Guthrie Robert
Huang Tai-Nang
G. Hull Kenneth
Sidduri Achytharao
Wright Tilley Jefferson
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of TR200000482T2 publication Critical patent/TR200000482T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/30—Metal salts; Chelates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Burada tarif edildigi gibi, formül (I) olan X, X', Z ve Y'nin sartnamede tarif edildigi gibi oldugu ve VCAM-1 hücreleri ile VLA-4 çikaran hücreler arasinda meydana gelen baglanmayi inhibe edici aktivite gösterdikleri bilesikler. Bu bilesikler. Bu bilesikler, semptomlari ve/veya harabiyeti VCAM-1'in VLA-4 çikaran hücrelere baglanmasi ile ilgili olan hastaliklarin tedavisinde yararlidir. Formül (I).
TR2000/00482T 1997-08-22 1998-08-13 N-Aroilfenilalanin türevleri. TR200000482T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5671897P 1997-08-22 1997-08-22

Publications (1)

Publication Number Publication Date
TR200000482T2 true TR200000482T2 (tr) 2000-06-21

Family

ID=22006187

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00482T TR200000482T2 (tr) 1997-08-22 1998-08-13 N-Aroilfenilalanin türevleri.

Country Status (32)

Country Link
EP (1) EP1005445B1 (tr)
JP (1) JP3555876B2 (tr)
KR (1) KR100554815B1 (tr)
CN (1) CN100369888C (tr)
AT (1) ATE267801T1 (tr)
AU (1) AU739511B2 (tr)
BR (1) BR9811730B1 (tr)
CA (1) CA2301377C (tr)
CO (1) CO4990955A1 (tr)
DE (1) DE69824183T2 (tr)
DK (1) DK1005445T3 (tr)
EG (1) EG23729A (tr)
ES (1) ES2221197T3 (tr)
HR (1) HRP20000080A2 (tr)
HU (1) HU229362B1 (tr)
ID (1) ID24304A (tr)
IL (1) IL134550A (tr)
MA (1) MA26533A1 (tr)
MY (1) MY138140A (tr)
NO (1) NO20000841D0 (tr)
NZ (1) NZ502813A (tr)
PE (2) PE107399A1 (tr)
PL (1) PL193283B1 (tr)
PT (1) PT1005445E (tr)
RU (1) RU2220950C2 (tr)
SA (1) SA98190557B1 (tr)
TR (1) TR200000482T2 (tr)
TW (1) TW490458B (tr)
UY (1) UY25151A1 (tr)
WO (1) WO1999010312A1 (tr)
YU (1) YU9600A (tr)
ZA (1) ZA987604B (tr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
ATE249421T1 (de) 1997-06-23 2003-09-15 Tanabe Seiyaku Co Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JP2002504534A (ja) * 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド α４インテグリンの阻害剤としてのフェニルアラニン誘導体
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
ATE353640T1 (de) * 1998-03-27 2007-03-15 Genentech Inc Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
BR0007663A (pt) 1999-01-22 2002-05-07 Elan Pharm Inc Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
AR035476A1 (es) 1999-01-22 2004-06-02 Elan Pharm Inc Compuestos heteroarilo y heterociclicos con anillo fusionado, los cuales inhiben la adhesion de leucocitos mediada por vla-4, composiciones farmaceuticas, el uso de las mismas para la manufactura de un medicamento y un metodo para fijar vla-4 en una muestra biologica
AU3348800A (en) 1999-01-22 2000-08-07 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
AU2623900A (en) * 1999-01-22 2000-08-07 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1213025C (zh) 1999-02-18 2005-08-03 霍夫曼-拉罗奇有限公司 硫代酰胺衍生物
DK1154987T3 (da) 1999-02-18 2004-08-09 Hoffmann La Roche Phenylalaninolderivater
WO2000051974A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists
WO2000068213A1 (en) * 1999-05-05 2000-11-16 Aventis Pharma Limited Substituted bicyclic compounds
WO2000068223A1 (en) 1999-05-05 2000-11-16 Aventis Pharma Limited Ureas and their use as cell adhesion modulators
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
WO2001012186A1 (en) * 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
US6420418B1 (en) 1999-08-16 2002-07-16 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
ES2288871T3 (es) * 1999-09-24 2008-02-01 Genentech, Inc. Derivados de tirosina.
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
WO2001030781A2 (en) * 1999-10-20 2001-05-03 Tanabe Seiyaku Co., Ltd. INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
US6897225B1 (en) 1999-10-20 2005-05-24 Tanabe Seiyaku Co., Ltd. Inhibitors of αLβ2 mediated cell adhesion
ATE355269T1 (de) 1999-11-18 2006-03-15 Ajinomoto Kk Phenylalaninderivate
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
RU2266901C2 (ru) * 1999-12-06 2005-12-27 Ф.Хоффманн-Ля Рош Аг 4-пиримидинил-n-ацил-l-фенилаланины и фармацевтическая композиция
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
AU2224901A (en) 1999-12-28 2001-07-09 Ajinomoto Co., Inc. Novel phenylalanine derivatives
IL149758A0 (en) 1999-12-28 2002-11-10 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2001242743A1 (en) 2000-03-23 2001-10-03 Ajinomoto Co. Inc. Novel phenylalanine derivative
EP1332132B1 (en) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
US20020035104A1 (en) 2000-08-18 2002-03-21 Genentech, Inc. Integrin receptor inhibitors
CA2420040C (en) 2000-08-18 2009-02-03 Ajinomoto Co., Inc. New phenylalanine derivatives
MY129000A (en) * 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
AU2001288114B2 (en) 2000-09-25 2006-04-27 Toray Industries, Inc. Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
EP1323711B1 (en) * 2000-09-29 2006-11-15 Ajinomoto Co., Inc. Novel phenylalanine derivatives
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
AU2003208105C1 (en) * 2002-02-07 2009-08-13 J-Pharma Co., Ltd. Aromatic amino acid derivatives and medicinal compositions
ATE464299T1 (de) 2002-02-20 2010-04-15 Ajinomoto Kk Neues phenylalaninderivat
CA2484954C (en) * 2002-04-30 2010-02-09 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
WO2004103967A2 (en) 2003-05-20 2004-12-02 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
ZA200605587B (en) 2003-12-22 2008-02-27 Ajinomoto Kk Novel phenylalanine derivative
US7205310B2 (en) 2004-04-30 2007-04-17 Elan Pharmaceuticals, Inc. Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7795448B2 (en) 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EA013080B1 (ru) 2005-06-09 2010-02-26 Юсб Фарма С.А. 2,6-хинолинильные производные, способы их получения и их применение
ATE462408T1 (de) * 2006-01-18 2010-04-15 Hoffmann La Roche Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007101165A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
CA2641160A1 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
WO2008064823A1 (en) * 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
NZ589086A (en) 2008-04-11 2012-09-28 Merrimack Pharmaceuticals Inc Human serum albumin (HSA) linkers and conjugates thereof
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN102946882B (zh) * 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のｇｌｐ−１受容体安定化薬および調節薬
EP2643295B1 (en) * 2010-11-26 2016-04-13 Chiesi Farmaceutici S.p.A. Glycine derivatives and their use as muscarinic receptor antagonists
EP2713722B1 (en) 2011-05-31 2017-03-15 Receptos, LLC Novel glp-1 receptor stabilizers and modulators
MX365923B (es) * 2011-12-12 2019-06-20 Celgene Int Ii Sarl Derivados de acido carboxilico que comprenden cuatro ciclos, que actuan como moduladores del receptor del peptido 1 similar al glucagon (glp-1) para terapia de enfermedades como la diabetes.
CA2857127A1 (en) * 2012-01-27 2013-08-01 F. Hoffmann-La Roche Ag Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1
WO2014201172A1 (en) * 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
KR20170052526A (ko) 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 다발성 경화증에 대한 병용 치료
KR102564946B1 (ko) 2014-07-25 2023-08-08 리셉토스 엘엘씨 신규 glp-1 수용체 조절제
WO2016094729A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
LT3873884T (lt) 2018-10-30 2025-03-10 Gilead Sciences, Inc. 3-(chinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diono dariniai kaip alfa4beta7 integrino inhibitoriai, skirti uždegiminių ligų gydymui
PL3873900T3 (pl) 2018-10-30 2025-06-02 Gilead Sciences, Inc. Imidazo[1,2-a]pirydynowe pochodne jako inhibitory integryny alpha4beta7 do leczenia chorób zapalnych
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN115340857B (zh) * 2022-08-24 2024-03-26 宁波锋成先进能源材料研究院有限公司 一种原位自乳化纳米驱油剂及其制备方法和应用
WO2025216810A1 (en) 2024-04-10 2025-10-16 Maxymune Therapeutics, Inc. Phenylalanine-based lat1 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE75693B1 (en) * 1990-07-10 1997-09-10 Janssen Pharmaceutica Nv HIV-inhibiting benzeneacetamide derivatives
CA2191979A1 (en) * 1994-06-20 1995-12-28 Muneo Takatani Condensed imidazole compounds, their production and use
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
ATE212978T1 (de) * 1996-03-29 2002-02-15 Searle & Co Para-substituierte phenylpropansäure derivate als integrin-antagonisten
DE19654483A1 (de) * 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate

Also Published As

Publication number Publication date
RU2000106434A (ru) 2004-01-20
ID24304A (id) 2000-07-13
EG23729A (en) 2007-06-28
CN100369888C (zh) 2008-02-20
PT1005445E (pt) 2004-09-30
KR100554815B1 (ko) 2006-02-22
HRP20000080A2 (en) 2000-12-31
IL134550A (en) 2005-12-18
RU2220950C2 (ru) 2004-01-10
MA26533A1 (fr) 2004-12-20
UY25151A1 (es) 2001-01-31
ES2221197T3 (es) 2004-12-16
HUP0003642A2 (hu) 2001-02-28
ZA987604B (en) 1999-07-28
JP2001514162A (ja) 2001-09-11
SA98190557A (ar) 2005-12-03
CO4990955A1 (es) 2000-12-26
SA98190557B1 (ar) 2006-08-20
EP1005445B1 (en) 2004-05-26
WO1999010312A1 (en) 1999-03-04
CN1281430A (zh) 2001-01-24
TW490458B (en) 2002-06-11
BR9811730B1 (pt) 2014-04-08
DK1005445T3 (da) 2004-10-04
NO20000841L (no) 2000-02-21
DE69824183T2 (de) 2005-04-21
PL193283B1 (pl) 2007-01-31
CA2301377C (en) 2009-10-06
BR9811730A (pt) 2000-09-05
PE107399A1 (es) 1999-11-03
IL134550A0 (en) 2001-04-30
PE111299A1 (es) 1999-11-20
KR20010023178A (ko) 2001-03-26
NO20000841D0 (no) 2000-02-21
HU229362B1 (en) 2013-11-28
EP1005445A1 (en) 2000-06-07
AU9262098A (en) 1999-03-16
WO1999010312B1 (en) 1999-06-03
ATE267801T1 (de) 2004-06-15
DE69824183D1 (de) 2004-07-01
PL338857A1 (en) 2000-11-20
CA2301377A1 (en) 1999-03-04
YU9600A (sh) 2002-03-18
JP3555876B2 (ja) 2004-08-18
HUP0003642A3 (en) 2001-11-28
AU739511B2 (en) 2001-10-11
MY138140A (en) 2009-04-30
NZ502813A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
TR200000482T2 (tr) N-Aroilfenilalanin türevleri.
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
TR199700803T1 (tr) Trombin-inhibitörleri olarak yeni dipeptidik amidinler.
TR199901305T2 (tr) Calpain-önleyicileri olarak ketonbenzamidler
TR199800436A2 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
TR200000059T2 (tr) Piridin türevleri
TR200100672T2 (tr) Yeni izoksazolinon antibakteriyel ajanları
ES2160408T3 (es) Trifluorfenil-triazolpirimidinas fungicidas.
DE59803845D1 (de) Sulfinsäurederivate und deren herstellung und verwendung
TR200102800T2 (tr) Yeni bileşikler.
TR200102025T2 (tr) Dopamin-D3-Reseptör afinitesine sahip triazol bileşikleri
TR200101124T2 (tr) N-(2-aril-propiyonil)-sülfonamidler ve bunları içeren farmasötik preparasyonlar.
MY126972A (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
BR0016172A (pt) 4-piridinil-n-acil-l-fenilalaninas
DE69821530D1 (de) Dihydrobenzifurane
TR200002580T2 (tr) Hücre çoğalmasının engellenmesinde kullanılan ikameli bisindolimaleimitler
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
TR200101979T2 (tr) Antidepresyon tedavisi için 5HT1 antagonistleri.
TR200103004T2 (tr) Pirolidinkarbonilamino siklik disülfitler.
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
BR9808210A (pt) Befeniloxazolinas dissubstituìdas
AU758194C (en) Novel benzimidazoles and benzoxazoles